JP2023510219A5 - - Google Patents

Info

Publication number
JP2023510219A5
JP2023510219A5 JP2022540871A JP2022540871A JP2023510219A5 JP 2023510219 A5 JP2023510219 A5 JP 2023510219A5 JP 2022540871 A JP2022540871 A JP 2022540871A JP 2022540871 A JP2022540871 A JP 2022540871A JP 2023510219 A5 JP2023510219 A5 JP 2023510219A5
Authority
JP
Japan
Prior art keywords
human insulin
γglu
desb30 human
eicosanedioyl
insulin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022540871A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023510219A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2020/141023 external-priority patent/WO2021136296A1/zh
Publication of JP2023510219A publication Critical patent/JP2023510219A/ja
Publication of JP2023510219A5 publication Critical patent/JP2023510219A5/ja
Pending legal-status Critical Current

Links

JP2022540871A 2019-12-30 2020-12-29 インスリン誘導体 Pending JP2023510219A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201911398378.0 2019-12-30
CN201911398378 2019-12-30
CN202011057926 2020-09-29
CN202011057926.6 2020-09-29
PCT/CN2020/141023 WO2021136296A1 (zh) 2019-12-30 2020-12-29 胰岛素衍生物

Publications (2)

Publication Number Publication Date
JP2023510219A JP2023510219A (ja) 2023-03-13
JP2023510219A5 true JP2023510219A5 (cg-RX-API-DMAC7.html) 2026-01-21

Family

ID=76687317

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2022540871A Pending JP2023510219A (ja) 2019-12-30 2020-12-29 インスリン誘導体
JP2022540767A Pending JP2023510206A (ja) 2019-12-30 2020-12-29 インスリン誘導体
JP2025128114A Pending JP2025161829A (ja) 2019-12-30 2025-07-31 インスリン誘導体

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022540767A Pending JP2023510206A (ja) 2019-12-30 2020-12-29 インスリン誘導体
JP2025128114A Pending JP2025161829A (ja) 2019-12-30 2025-07-31 インスリン誘導体

Country Status (10)

Country Link
US (5) US20240025957A1 (cg-RX-API-DMAC7.html)
EP (3) EP4086279A4 (cg-RX-API-DMAC7.html)
JP (3) JP2023510219A (cg-RX-API-DMAC7.html)
KR (2) KR20220121833A (cg-RX-API-DMAC7.html)
CN (12) CN118754967A (cg-RX-API-DMAC7.html)
AU (2) AU2020417892B2 (cg-RX-API-DMAC7.html)
BR (2) BR112022013009A2 (cg-RX-API-DMAC7.html)
CA (2) CA3166495A1 (cg-RX-API-DMAC7.html)
MX (2) MX2022008130A (cg-RX-API-DMAC7.html)
WO (3) WO2021136302A1 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020418207A1 (en) * 2019-12-30 2022-08-25 Gan & Lee Pharmaceuticals Co., Ltd. Long-acting GLP-1 compound
BR112022013009A2 (pt) * 2019-12-30 2022-09-06 Gan & Lee Pharmaceuticals Co Ltd Derivados de insulina, composição farmacêutica, uso do derivado da insulina e métodos para tratar ou prevenir diabetes, para aumentar a capacidade de um derivado de insulina e para aumentar a potência de um derivado de insulina
KR20240118914A (ko) 2021-01-20 2024-08-05 바이킹 테라퓨틱스 인코포레이티드 대사 및 간 질환 치료를 위한 조성물 및 방법
CA3217734A1 (en) * 2021-05-24 2022-12-01 Baoye ZHENG A novel acylated insulin analog
WO2022268208A1 (zh) * 2021-06-25 2022-12-29 甘李药业股份有限公司 含酰化胰岛素的药物组合物
CA3231953A1 (en) 2021-09-15 2023-03-23 Brian Lian Compositions and methods for the treatment of metabolic and liver disorders
CN116162147B (zh) * 2021-11-24 2023-10-03 成都奥达生物科技有限公司 一种长效胰岛素类似物
WO2023143458A1 (zh) * 2022-01-28 2023-08-03 甘李药业股份有限公司 酰化胰岛素
CN117586376A (zh) * 2022-08-10 2024-02-23 成都奥达生物科技有限公司 一种长效胰岛素化合物
CN120731085A (zh) * 2023-03-02 2025-09-30 甘李药业股份有限公司 一种glp-1化合物的医药用途
JP2026517987A (ja) * 2023-05-24 2026-06-02 ザ ユナイテッド バイオテクノロジー(ヘンチン)シーオー.,エルティーディー. インスリン誘導体およびその使用
CN116327890B (zh) * 2023-05-29 2023-12-08 北京先为达生物科技有限公司 口服递送的组合物及其应用
CN116789801B (zh) * 2023-08-21 2023-11-14 南京赛诺生物技术有限公司 新型胰岛素衍生物及其用途
AU2024358560A1 (en) * 2023-10-09 2026-05-14 Gan & Lee Pharmaceuticals Co., Ltd. Glp -1 peptide composition and use thereof
WO2025098457A1 (zh) 2023-11-07 2025-05-15 甘李药业股份有限公司 用于降糖的酰化胰岛素
CN122555570A (zh) * 2023-11-08 2026-08-11 甘李药业股份有限公司 包含胰岛素衍生物的药物组合物的治疗用途
WO2025228255A1 (zh) * 2024-04-28 2025-11-06 正大天晴药业集团股份有限公司 酰化人胰岛素类似物
CN120887973A (zh) * 2024-06-13 2025-11-04 惠升生物制药股份有限公司 一种长效酰化胰岛素衍生物及其应用

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ199391A (en) 1981-01-02 1985-12-13 Genentech Inc Chimeric polypeptides comprising a proinsulin sequence,and preparation by recombinant dna technique;production of human insulin
DK58285D0 (da) 1984-05-30 1985-02-08 Novo Industri As Peptider samt fremstilling og anvendelse deraf
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
DK336188D0 (da) 1988-06-20 1988-06-20 Nordisk Gentofte Propeptider
HUT56857A (en) 1988-12-23 1991-10-28 Novo Nordisk As Human insulin analogues
IL93282A (en) 1989-02-09 1995-08-31 Lilly Co Eli Insulin analogues
NZ273285A (en) 1993-09-17 1997-10-24 Novo Nordisk As Insulin derivatives and compositions thereof
WO1995016708A1 (en) 1993-12-17 1995-06-22 Novo Nordisk A/S Proinsulin-like compounds
US6500645B1 (en) 1994-06-17 2002-12-31 Novo Nordisk A/S N-terminally extended proteins expressed in yeast
KR0150565B1 (ko) 1995-02-15 1998-08-17 김정재 유전자 조환에 의한 사람 인슐린 전구체의 제조 및 이를 이용한 인슐린의 제조방법
IL118127A0 (en) 1995-05-05 1996-09-12 Lilly Co Eli Single chain insulin with high bioactivity
AU2004261353B2 (en) 2003-08-05 2009-12-10 Novo Nordisk A/S Novel insulin derivatives
JP5202338B2 (ja) * 2006-02-27 2013-06-05 ノボ・ノルデイスク・エー/エス 新規インシュリン誘導体
AU2007247109B2 (en) 2006-05-09 2012-03-15 Novo Nordisk A/S Insulin derivative
CN101573133B (zh) 2006-07-31 2014-08-27 诺沃-诺迪斯克有限公司 Peg化延长的胰岛素
EP2170945A1 (en) 2007-07-16 2010-04-07 Novo Nordisk A/S Protease stabilized, pegylated insulin analogues
AU2008288413B2 (en) 2007-08-15 2013-09-26 Novo Nordisk A/S Insulin analogues with an acyl and aklylene glycol moiety
WO2009022006A1 (en) * 2007-08-15 2009-02-19 Novo Nordisk A/S Insulins with an acyl moiety comprising repeating units of alkylene glycol containing amino acids
US20100292133A1 (en) 2007-09-05 2010-11-18 Novo Nordisk A/S Truncated glp-1 derivaties and their therapeutical use
HUE032284T2 (en) * 2008-03-18 2017-09-28 Novo Nordisk As Protease-stabilized, acylated insulin analogues
CN102149411A (zh) * 2008-09-12 2011-08-10 诺沃—诺迪斯克有限公司 酰化肽或蛋白的方法
BR112012016853A2 (pt) * 2010-01-12 2017-10-17 Novo Nordisk As "composições farmacêuticas para administração oral de peptídeos de insulina".
KR20130018410A (ko) 2010-03-26 2013-02-21 노보 노르디스크 에이/에스 새로운 글루카곤 유사체
EP2720711A1 (en) * 2011-06-15 2014-04-23 Novo Nordisk A/S Multi substituted insulins
CN104788556A (zh) 2011-12-15 2015-07-22 上海恒瑞医药有限公司 人胰岛素类似物及其酰化衍生物
EP2836508B1 (en) 2012-04-11 2016-06-29 Novo Nordisk A/S Insulin formulations
WO2014009316A1 (en) 2012-07-09 2014-01-16 Novo Nordisk A/S Novel use of insulin derivatives
JP2017506640A (ja) 2014-02-14 2017-03-09 セントローズ, エルエルシー 細胞外標的化薬物共役体
AR099569A1 (es) * 2014-02-28 2016-08-03 Novo Nordisk As Derivados de insulina y los usos médicos de estos
CN105820233B (zh) 2015-01-04 2021-06-15 甘李药业股份有限公司 一种胰岛素衍生物的制备方法
JP6737793B2 (ja) * 2015-01-29 2020-08-12 ノヴォ ノルディスク アー/エス 錠剤コアとポリビニルアルコールコーティングとを含む経口インスリン投与のための医薬組成物
BR112018002416A2 (pt) * 2015-08-25 2018-09-18 Novo Nordisk As derivados de insulina e seus usos médicos
EP3341401A1 (en) * 2015-08-25 2018-07-04 Novo Nordisk A/S Novel insulin derivatives and the medical uses hereof
EP3341991B1 (en) * 2015-08-27 2020-07-08 Haldor Topsøe A/S High tap density lithium positive electrode active material, intermediate and process of preparation
US10815287B2 (en) 2016-08-02 2020-10-27 Jiangsu Hengrui Medicine Co., Ltd. Acylated derivative of human insulin or analogue thereof
ES2886837T3 (es) 2016-12-16 2021-12-21 Novo Nordisk As Composiciones farmacéuticas que contienen insulina
JOP20190273A1 (ar) * 2017-05-26 2019-11-24 Lilly Co Eli مركب إنسولين معالج بأسيل
AU2020418207A1 (en) * 2019-12-30 2022-08-25 Gan & Lee Pharmaceuticals Co., Ltd. Long-acting GLP-1 compound
BR112022013009A2 (pt) * 2019-12-30 2022-09-06 Gan & Lee Pharmaceuticals Co Ltd Derivados de insulina, composição farmacêutica, uso do derivado da insulina e métodos para tratar ou prevenir diabetes, para aumentar a capacidade de um derivado de insulina e para aumentar a potência de um derivado de insulina
WO2023143458A1 (zh) * 2022-01-28 2023-08-03 甘李药业股份有限公司 酰化胰岛素

Similar Documents

Publication Publication Date Title
US20250032589A1 (en) Insulin Derivative
JP2023510206A5 (cg-RX-API-DMAC7.html)
JP2023510218A5 (cg-RX-API-DMAC7.html)
JP2023510218A (ja) 長時間作用型glp-1化合物
US20250340610A1 (en) Acylated insulin
US20250262282A1 (en) Acylated Insulin-Containing Pharmaceutical Composition
EA050813B1 (ru) Производное инсулина
HK40109784A (en) Insulin derivative
EA050726B1 (ru) Производное инсулина
HK40070502A (zh) 胰岛素衍生物
HK40070502B (zh) 胰岛素衍生物
HK40115534A (en) Long-acting glp-1 compound